Log in to save to my catalogue

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a larg...

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a larg...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9f896a44cef44c188a88370316d2d5e1

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study

About this item

Full title

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study

Publisher

England: BioMed Central Ltd

Journal title

BMC neurology, 2019-09, Vol.19 (1), p.224-224, Article 224

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly-inherited progressive muscular dystrophy caused by de-repression of the DUX4 gene, which causes disease by a toxic-gain-of-function. As molecularly targeted drugs move from preclinical testing into human trials, it is essential that we validate clinical trial tools and methodology to fac...

Alternative Titles

Full title

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_9f896a44cef44c188a88370316d2d5e1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9f896a44cef44c188a88370316d2d5e1

Other Identifiers

ISSN

1471-2377

E-ISSN

1471-2377

DOI

10.1186/s12883-019-1452-x

How to access this item